A5077041613- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Bladder and Urothelial Cancer Treatments
- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Cancer, Stress, Anesthesia, and Immune Response
- Inflammatory Biomarkers in Disease Prognosis
- Economic and Financial Impacts of Cancer
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Adrenal and Paraganglionic Tumors
- Hepatocellular Carcinoma Treatment and Prognosis
- Global Cancer Incidence and Screening
- Tryptophan and brain disorders
- Nutrition and Health in Aging
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
Roswell Park Comprehensive Cancer Center
2023-2025
Tokyo Medical and Dental University
2024-2025
Icahn School of Medicine at Mount Sinai
2021-2024
Mount Sinai Beth Israel
2020-2024
King Edward Medical University
2024
Japanese Foundation For Cancer Research
2019-2023
The Cancer Institute Hospital
2020-2023
Musashino Red Cross Hospital
2018-2020
National Cancer Institute
2020
Tokyo National Hospital
2019
No meta-analysis has assessed the pooled frequencies of adverse events (AEs) induced by concomitant nivolumab plus ipilimumab regimen for anticancer-medications-naïve malignancies. Furthermore, no compared detailed safety profiles between four doses 3 mg/kg 1 every weeks (N3I1) and (N1I3). Objectives this study was estimating AE frequencies, comparison N3I1 N1I3 regimens.Four major electronic databases were searched; both interventional observational studies included. All primary cancer...
TPS319 Background: Immune checkpoint inhibitors (ICIs) have shown limited benefit in CRC outside the microsatellite instability high (MSI-H) population. Deficient cytotoxic T lymphocyte (CTL) trafficking to tumor microenvironment (TME) and excess pro-tumorigenic cytokines immunosuppressive cells may contribute primary ICI resistance stable (MSS) CRC. Selective enrichment of with specific chemokine receptors enhance antitumor immunity. Studies highlight role IL-12 improving progression-free...
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers ATC treated lenvatinib lacking. The aim this study was to explore whether neutrophil-to-lymphocyte ratio (NLR) can be a marker lenvatinib. Patients and Methods: We retrospectively analyzed prognostic significance NLR in 13 Results: disease control rate better lower (<8; 89%) than higher (≥8; 25%) (p=0.05). Median progression-free survival overall were longer (4.0...
Indoleamine 2,3-dioxygenase 1 (IDO1), which catabolizes tryptophan, is a potential target to unlock the immunosuppressive tumor microenvironment. Correlations between IDO1 and immune checkpoint inhibitor (ICI) efficacy remain unclear. Herein, we investigated transcript expression across cancers clinical outcome correlations. High transcripts were more frequent in uterine (54.2%) ovarian cancer (37.2%) but varied within malignancies. RNA was associated with high of PD-L1 (immune ligand),...
ABSTRACT Background Preoperative chemoradiation (CRT) followed by surgery for localized esophageal and gastroesophageal junction adenocarcinoma (EGAC) is a standard of care with pathologic complete response (pCR) rate 20%. We evaluated novel combination trifluridine/tipiracil oxaliplatin as induction chemotherapy (IC) CRT. Methods enrolled patients potentially resectable EGAC (T3, T4aN0, or node‐positive disease) in this open‐label, single‐arm, multicenter, Phase II trial between January...
2625 Background: Immune checkpoint inhibitors (ICIs) have become a standard treatment, yet no universal biomarker consistently predicts prolonged survival across cancer types. While multiple biomarkers been proposed, they not systematically compared or evaluated in tumor-agnostic manner. This study comprehensively investigates the impact of 397 immunoregulatory transcripts and other factors on patients with treated ICIs. Methods: The Profile-Related Evidence Determining Individualized Cancer...
e23005 Background: Withdrawal without a defined reason (WWDR) can introduce unintended bias and reduce generalizability in therapeutic cancer clinical trials. Changes patients’ perceived risks versus benefits of participation trials are the main drivers for withdrawal. Commonly employed retention strategies include supportive care, telemedicine, patient education materials. However, frequency effectiveness trial-endorsed approaches to not well defined. Methods: We extracted WWDR rates...
e23003 Background: Patient withdrawal in oncology clinical trials ranges from 5% to 45%, posing significant threats trial integrity. High attrition rates can lead underpowered studies, selection bias, diminished generalizability, and wasted resources. Despite the importance of mitigating withdrawal, reasons extent are often poorly documented. The lack standardized practices for documenting reasons, coupled with infrequent use written consent forms, introduces ambiguity interpreting patient...
e23014 Background: Withdrawal without a defined reason (WWDR) undermines the reliability and interpretability of clinical trial results poses critical challenge for design. The underlying factors driving WWDR remain poorly understood. This study seeks to identify trial-level associated with that can be intervened upon improve participant retention. Methods: We systematically reviewed therapeutic phase 3 oncology trials registered on ClinicalTrials.gov from August 20, 2014 2024. Supportive...
2642 Background: PD-1, PD-L1, and CTLA-4 blockade are standard therapies in multiple solid tumors, novel agents targeting alternative co-stimulatory co-inhibitory immune checkpoints under development. Immune checkpoint inhibitors well known to cause immune-related adverse events (irAEs) studies reported the accurate incidence of irAEs from blockade. With increasing investigation anticipated approval immunotherapy agents, understanding their toxicity profiles is critical. Methods: We...
e23155 Background: The globalization of oncology trials has created opportunities for emerging regions to play larger roles in clinical research. This study evaluated trends the establishment new trial sites Latin America (LATAM) compared other and assessed participant representation. Methods: We analyzed phase 3 posted on ClinicalTrials.gov from January 2013 December 2022. Trials with at least one newly initiated LATAM site, defined by date first enrollment, were included. Data site...